» Articles » PMID: 20338963

Modeling the 4D Study: Statins and Cardiovascular Outcomes in Long-term Hemodialysis Patients with Diabetes

Overview
Specialty Nephrology
Date 2010 Mar 27
PMID 20338963
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Objectives: Randomized, controlled trials (RCTs) are the gold standard for defining causal inferences but are sometimes not feasible because of cost, ethical, or time considerations. We explored the accuracy and potential use of a "simulated trial" through the modeling of a previously published RCT, Die Deutsche Diabetes Dialyse Studie (4D Study), a landmark study that investigated the cardiovascular benefit of atorvastatin use in 1255 patients with ESRD.

Design, Setting, Participants, & Measurements: Using a large historical database of interventions and outcomes in dialysis patients, we conducted an observational model of the 4D Study in dialysis patients who had type 2 diabetes and were prescribed a statin (5144 patients) and matched to a non-statin user (5144 control subjects) before multivariate modeling. Inclusion, exclusion, and outcome parameters of the study, as prespecified by the 4D Study, were strictly modeled in this analysis.

Results: In covariate- and propensity-adjusted Cox regression, statin use (versus nonuse) was associated with a decrease in the composite primary outcome of cardiac death, nonfatal myocardial infarction, and stroke. Statin use was also associated with a decrease in cardiovascular mortality and all cardiac events combined. The hazard ratios in this observational model were numerically comparable to the hazard ratios reported in the 4D Study; however, because of the larger number of patients "enrolled," results in this simulated study achieved statistical significance.

Conclusions: Statin use was associated with some cardiovascular benefit in a simulated trial of patients with ESRD; however, the size of benefit was considerably smaller than that seen in the general population. Such simulated trials may represent an exploratory, cost-effective option when RCTs are not immediately feasible.

Citing Articles

Statin Therapy for Hyperlipidemic Patients With Chronic Kidney Disease and End-Stage Renal Disease: A Retrospective Cohort Study Based on 925,418 Adults in Taiwan.

Sung F, Jong Y, Muo C, Hsu C, Tsai W, Hsu Y Front Pharmacol. 2022; 13:815882.

PMID: 35308209 PMC: 8930832. DOI: 10.3389/fphar.2022.815882.


Cardiovascular Mortality Can Be Predicted by Heart Rate Turbulence in Hemodialysis Patients.

Braunisch M, Mayer C, Bauer A, Lorenz G, Haller B, Rizas K Front Physiol. 2020; 11:77.

PMID: 32116784 PMC: 7027389. DOI: 10.3389/fphys.2020.00077.


Association of Continuation of Statin Therapy Initiated Before Transition to Chronic Dialysis Therapy With Mortality After Dialysis Initiation.

Streja E, Gosmanova E, Molnar M, Soohoo M, Moradi H, Potukuchi P JAMA Netw Open. 2019; 1(6):e182311.

PMID: 30646217 PMC: 6324660. DOI: 10.1001/jamanetworkopen.2018.2311.


The effect of chronic kidney disease on lipid metabolism.

Dincer N, Dagel T, Afsar B, Covic A, Ortiz A, Kanbay M Int Urol Nephrol. 2018; 51(2):265-277.

PMID: 30519980 DOI: 10.1007/s11255-018-2047-y.


A meta-analysis of the effects of statin treatment on cardiovascular events and all-cause mortality in diabetic dialysis patients.

Yang M, Xie X, Yuan W Int J Clin Exp Med. 2015; 8(6):8415-24.

PMID: 26309494 PMC: 4538050.


References
1.
Foley R, Parfrey P, Sarnak M . Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis. 1998; 32(5 Suppl 3):S112-9. DOI: 10.1053/ajkd.1998.v32.pm9820470. View

2.
Sacks F, Pfeffer M, Moye L, Rouleau J, Rutherford J, Cole T . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996; 335(14):1001-9. DOI: 10.1056/NEJM199610033351401. View

3.
Broome C, Loonsk J . Public Health Information Network--improving early detection by using a standards-based approach to connecting public health and clinical medicine. MMWR Suppl. 2005; 53:199-202. View

4.
Lowrie E, Lew N . Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis. 1990; 15(5):458-82. DOI: 10.1016/s0272-6386(12)70364-5. View

5.
Kalantar-Zadeh K, Ikizler T, Block G, Avram M, Kopple J . Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis. 2003; 42(5):864-81. DOI: 10.1016/j.ajkd.2003.07.016. View